The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,004,819 in first-year total cost, median $502,410.
Most frequent study sections
- Cancer Biomarkers Study Section[CBSS]1
- Clinical and Integrative Cardiovascular Sciences Study Section[CICS]1
Most frequent institutions
- UNIV OF NORTH CAROLINA CHAPEL HILL1
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | A Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction1R01AG058659-01 | SIMON, MARC A | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $649,113 | CICS |
| 2018 | Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer1R37CA226969-01 | BAE-JUMP, VICTORIA LIN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $355,706 | CBSS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.